Brief: Hyloris, PFH Partner To Develop Vulvovaginal Candidiasis Product

Hyloris Pharmaceuticals SA

05/02/2021 06:11

Feb 5 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * HYLORIS AND PURNA FEMALE HEALTHCARE (PFH) ANNOUNCE
PARTNERSHIP
TO DEVELOP NOVEL WOMEN'S HEALTH PRODUCT
    * PARTNERSHIP TO DEVELOP AND COMMERCIALISE COMBINATION
THERAPY FOR
TREATMENT OF SEVERE AND RECURRENT VULVOVAGINAL CANDIDIASIS
(RVVC)
    * HYLORIS HAS COMMITTED TO MILESTONE RELATED INVESTMENTS OF
UP TO
€4.3 MILLION IN PFH (OF WHICH €1.27 MILLION AT SIGNING)
    * WE LOOK FORWARD TO COMMENCING CLINICAL TRIALS IN 2021 -
PFH
MANAGING DIRECTOR

Source text for Eikon:  ID:nGNE9sFSxR 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))